OncoMatch/Clinical Trials/NCT06244225
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Is NCT06244225 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Donafenib； Sintilimab； HAIC for hepatocellular carcinoma.
Treatment: Donafenib； Sintilimab； HAIC — This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: local treatment for liver cancer
Receipt of local treatment for liver cancer within 4 weeks before the first dose.
Cannot have received: systemic treatment with traditional Chinese medicines with cancer indications or immunomodulators (thymosin, interferon, interleukin)
Exception: barring local use for controlling pleural fluid or ascites
Receipt of systemic treatment with traditional Chinese medicines with cancer indications or immunomodulators (including thymosin, interferon, and interleukin, barring local use for controlling pleural fluid or ascites) within 2 weeks before the first dose.
Lab requirements
Blood counts
Sufficient organ and bone marrow functions
Kidney function
Sufficient organ and bone marrow functions
Liver function
Child Pugh score of ≤ 7
Child Pugh score of ≤ 7. Sufficient organ and bone marrow functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify